Development of differential diagnosis for benign and malignant pheochromocytomas.
about
Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations.Peptide receptor radionuclide therapy for metastatic paragangliomas.Nuclear imaging to characterize adrenal tumors: Comparison with MRI.
P2860
Development of differential diagnosis for benign and malignant pheochromocytomas.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of differential diagnosis for benign and malignant pheochromocytomas.
@en
Development of differential diagnosis for benign and malignant pheochromocytomas.
@nl
type
label
Development of differential diagnosis for benign and malignant pheochromocytomas.
@en
Development of differential diagnosis for benign and malignant pheochromocytomas.
@nl
prefLabel
Development of differential diagnosis for benign and malignant pheochromocytomas.
@en
Development of differential diagnosis for benign and malignant pheochromocytomas.
@nl
P2093
P2860
P1476
Development of differential diagnosis for benign and malignant pheochromocytomas.
@en
P2093
Baohua Gao
Fanshan Kong
Zhishun Xu
P2860
P304
P356
10.1111/J.1442-2042.2008.02111.X
P577
2008-07-10T00:00:00Z